Sarepta Therapeutics annual capital expenditures (capex)
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sarepta Therapeutics Capital Expenditures (CapEx) Growth & History (SRPT)
Sarepta Therapeutics's capital expenditures (capex) was $102.0M for fiscal 2025.
View full Sarepta Therapeutics company overviewSarepta Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $102.0M | −$35.0M | −25.54% |
| 2024 | 2024-12-31 | $137.0M | $60.9M | +79.95% |
| 2023 | 2023-12-31 | $76.1M | $45.3M | +146.91% |
| 2022 | 2022-12-31 | $30.8M | −$7.7M | −19.92% |
| 2021 | 2021-12-31 | $38.5M | −$43.7M | −53.18% |
| 2020 | 2020-12-31 | $82.2M | $22.6M | +37.85% |
| 2019 | 2019-12-31 | $59.6M | −$1.5M | −2.50% |
| 2018 | 2018-12-31 | $61.2M | $49.2M | +409.64% |
| 2017 | 2017-12-31 | $12.0M | $6.7M | +124.68% |
| 2016 | 2016-12-31 | $5.3M | $1.9M | +57.04% |
| 2015 | 2015-12-31 | $3.4M | −$22.0M | −86.63% |
| 2014 | 2014-12-31 | $25.4M | $23.1M | +973.59% |
| 2013 | 2013-12-31 | $2.4M | $2.3M | +2094.44% |
| 2012 | 2012-12-31 | $108,000 | −$1.1M | −90.83% |
| 2011 | 2011-12-31 | $1.2M | $346,000 | +41.59% |
| 2010 | 2010-12-31 | $832,000 | −$99,000 | −10.63% |
| 2009 | 2009-12-31 | $931,000 | — | — |
Sarepta Therapeutics quarterly capital expenditures (capex)
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $555,000 | −$31.2M | −98.25% |
| Q1 2026 | 2026-03-31 | $2.1M | −$41.6M | −95.23% |
| Q4 2025 | 2025-12-31 | $3.6M | −$34.5M | −90.57% |
| Q3 2025 | 2025-09-30 | $22.9M | −$14.3M | −38.45% |
| Q2 2025 | 2025-06-30 | $31.8M | $2.6M | +9.01% |
| Q1 2025 | 2025-03-31 | $43.7M | $11.2M | +34.54% |
| Q4 2024 | 2024-12-31 | $38.1M | $19.0M | +100.02% |
| Q3 2024 | 2024-09-30 | $37.3M | $7.6M | +25.58% |
| Q2 2024 | 2024-06-30 | $29.2M | $11.3M | +62.86% |
| Q1 2024 | 2024-03-31 | $32.4M | $23.0M | +242.06% |
| Q4 2023 | 2023-12-31 | $19.0M | $11.1M | +139.06% |
| Q3 2023 | 2023-09-30 | $29.7M | $21.4M | +260.50% |
| Q2 2023 | 2023-06-30 | $17.9M | $8.8M | +97.28% |
| Q1 2023 | 2023-03-31 | $9.5M | $3.9M | +70.87% |
| Q4 2022 | 2022-12-31 | $8.0M | $5.8M | +261.02% |
| Q3 2022 | 2022-09-30 | $8.2M | −$1.0M | −10.93% |
| Q2 2022 | 2022-06-30 | $9.1M | $3.2M | +54.02% |
| Q1 2022 | 2022-03-31 | $5.6M | −$15.6M | −73.75% |
| Q4 2021 | 2021-12-31 | $2.2M | −$26.4M | −92.29% |
| Q3 2021 | 2021-09-30 | $9.2M | −$16.1M | −63.48% |
| Q2 2021 | 2021-06-30 | $5.9M | −$13.3M | −69.25% |
| Q1 2021 | 2021-03-31 | $21.1M | $12.0M | +131.90% |
| Q4 2020 | 2020-12-31 | $28.6M | $11.4M | +65.79% |
| Q3 2020 | 2020-09-30 | $25.3M | $15.9M | +168.35% |
| Q2 2020 | 2020-06-30 | $19.2M | $2.5M | +14.91% |
| Q1 2020 | 2020-03-31 | $9.1M | −$7.1M | −43.92% |
| Q4 2019 | 2019-12-31 | $17.3M | −$2.9M | −14.58% |
| Q3 2019 | 2019-09-30 | $9.4M | −$10.7M | −53.07% |
| Q2 2019 | 2019-06-30 | $16.7M | $8.0M | +91.81% |
| Q1 2019 | 2019-03-31 | $16.3M | $4.1M | +33.68% |
| Q4 2018 | 2018-12-31 | $20.2M | $16.3M | +418.16% |
| Q3 2018 | 2018-09-30 | $20.1M | $19.3M | +2526.27% |
| Q2 2018 | 2018-06-30 | $8.7M | $5.8M | +202.93% |
| Q1 2018 | 2018-03-31 | $12.2M | $7.7M | +172.47% |
| Q4 2017 | 2017-12-31 | $3.9M | $985,000 | +33.80% |
| Q3 2017 | 2017-09-30 | $765,000 | −$75,000 | −8.93% |
| Q2 2017 | 2017-06-30 | $2.9M | $2.5M | +585.20% |
| Q1 2017 | 2017-03-31 | $4.5M | $3.3M | +282.28% |
| Q4 2016 | 2016-12-31 | $2.9M | $1.8M | +168.57% |
| Q3 2016 | 2016-09-30 | $840,000 | −$307,000 | −26.77% |
| Q2 2016 | 2016-06-30 | $419,000 | −$218,000 | −34.22% |
| Q1 2016 | 2016-03-31 | $1.2M | $636,000 | +119.55% |
| Q4 2015 | 2015-12-31 | $1.1M | −$2.1M | −65.43% |
| Q3 2015 | 2015-09-30 | $1.1M | −$11.3M | −90.80% |
| Q2 2015 | 2015-06-30 | $637,000 | −$3.9M | −85.89% |
| Q1 2015 | 2015-03-31 | $532,000 | −$4.8M | −90.01% |
| Q4 2014 | 2014-12-31 | $3.1M | $2.5M | +416.28% |
| Q3 2014 | 2014-09-30 | $12.5M | $11.1M | +839.26% |
| Q2 2014 | 2014-06-30 | $4.5M | $4.1M | +959.86% |
| Q1 2014 | 2014-03-31 | $5.3M | $5.3M | +59077.78% |
| Q4 2013 | 2013-12-31 | $608,000 | $608,000 | — |
| Q3 2013 | 2013-09-30 | $1.3M | $1.3M | +3691.43% |
| Q2 2013 | 2013-06-30 | $426,000 | $292,000 | +217.91% |
| Q1 2013 | 2013-03-31 | $9,000 | $0 | 0.00% |
| Q4 2012 | 2012-12-31 | $0 | −$205,000 | — |
| Q3 2012 | 2012-09-30 | $35,000 | −$262,000 | −88.22% |
| Q2 2012 | 2012-06-30 | $134,000 | −$315,000 | −70.16% |
| Q1 2012 | 2012-03-31 | $9,000 | −$218,000 | −96.04% |
| Q4 2011 | 2011-12-31 | $205,000 | — | — |
| Q3 2011 | 2011-09-30 | $297,000 | $9,000 | +3.13% |
| Q2 2011 | 2011-06-30 | $449,000 | — | — |
| Q1 2011 | 2011-03-31 | $227,000 | — | — |
| Q3 2010 | 2010-09-30 | $288,000 | — | — |
Sarepta Therapeutics capital expenditures (capex) trends
Over the last five fiscal years, Sarepta Therapeutics's capital expenditures (capex) increased from $82.2M to $102.0M, a change of $19.8M. The latest reported quarter, Q2 2026, shows $555,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sarepta Therapeutics source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...